Biotechnology
Medical
Biopharmaceutical

Nektar Therapeutics

$32.08
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.29 (-0.90%) Today
-$0.29 (-0.90%) Today

Why Robinhood?

You can buy or sell NKTR and other stocks, options, ETFs, and crypto commission-free!

About

Nektar Therapeutics Common Stock, also called Nektar Therapeutics, is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. Read More It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.

Employees
618
Headquarters
San Francisco, California
Founded
1990
Market Cap
5.62B
Price-Earnings Ratio
8.89
Dividend Yield
0.00
Average Volume
2.70M
High Today
$32.88
Low Today
$32.06
Open Price
$32.81
Volume
536.29K
52 Week High
$108.23
52 Week Low
$29.22

Collections

Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Health
Therapy
Chemicals
Technology

News

TradingNewsNow12h

Current Fundamentals: Nektar Therapeutics (NASDAQ: NKTR)

Nektar Therapeutics trades as part of the healthcare sector and trades as part of the biotechnology industry. The company CEO is Howard W. Robin. Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company is researching and developing drugs for treating cancer, auto-immune disease and chronic pain. Previous Intraday Trading Performance: The NKTR stock showed a previous change of 0.62% with an open at 32.10 and ...

65
MarketWatchMar 15

Nektar Therapeutics Stock Quote (U.S.: Nasdaq)

All three major indexes climbed around 1%, and the Nasdaq Composite has seen its best start to a year since 2006. The U.S. and China have reportedly made progress on trade negotiations, outweighing negative sentiment from an extended government shutdown.

422
Yahoo FinanceMar 12

3 Stocks That Could Double Your Money

Nearly every week, a stock soars or sinks because of a Wall Street analyst's opinion. If a key analyst thinks a stock has better prospects than it did the previous week, that view often becomes a self-fulfilling prophecy, with the stock jumping. The opposite scenario frequently happens as well. Since analysts' opinions often carry so much weight, which stocks are they most bullish about? Three stocks that Wall Street especially loves right now are Editas Medicine (NASDAQ: EDIT), Nektar Therapeutics (NASDAQ...

1,142

Earnings

-$0.63
$1.36
$3.34
$5.33
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
β€”
Actual
Expected May 9, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.